Skip to main content
. 2024 Aug 19;34(10):1947–1958. doi: 10.4014/jmb.2407.07004

Table 3.

Reports on engineered bacterial therapeutics for metabolic disorder.

Chassis Target disease Genetically encoded biosensor Actuator Model Refs
L. lactis Obesity - GLP-1 C57BL/6 mice [54]
L. reuteri Nonalcoholic fatty liver disease - Interleukin-22 C57BL/6J mice [60]
L. reuteri Alcoholic liver disease - Interleukin-22 C57BL/6 mice [61]
L. lactis Diabetes - Proinsulin
Interleukin-10
NOD mice [62]
Lactobacillus paracasei Diabetic retinopathy - Angiotensin converting enzyme 2 C57BL/6J mice [63]
E. coli Nissle 1917 ΔthyA Enteric hyperoxaluria - Oxalate/formate antiporter
Oxalyl-CoA decarboxylase
Formyl-CoA trasferase
C57BL/6J mice
Cynomolgus monkey
[65]
E. coli Nissle 1917 ΔthyA, argR Hepatic encephalopathy - N-acetylglutamate synthase C57BL/6 mice
Cynomolgus monkey
Human (healthy)
[66]
E. coli Nissle 1917 ΔdapA Phenylketonuria - Phenylalanine transporter
Phenylalanine ammonia lyase
L-amino acid deaminase
C57BL/6 mice
Cynomolgus monkey
[67]
Trans-cinnamate-inducible sensor for the screening of phenylalanine ammonia lyase activity Phenylalanine transporter
Phenylalanine ammonia lyase mutant
L-amino acid deaminase
Cynomolgus monkey [68]
Small molecule-inducible sensor array for the regulation of enzyme expression - [69]